Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]
News [2550]
Articles [106]
Editorials [3]
Conferences [84]
elearning [20]
Science behind phase I clinical trials: targeting tumour cell development...
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
ASCO 2013 highlights
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
ASCO 2013 highlights ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
Crizotinib superior to chemo for advanced ALK positive NSCLC
Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Crizotinib superior to chemo for advanced ALK positive NSCLC ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
6 Jun 2013
Comment on progression free survival in lung cancer patients and the GALAXY-1...
Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA
Comment on progression free survival in lung cancer patients and the GALAXY-1 trial ( Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA )
3 Jun 2013
Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer
Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
3 Jun 2013
Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
3 Jun 2013
Nivolumab blocking PD1 in lung cancer and melanoma
Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA
Nivolumab blocking PD1 in lung cancer and melanoma ( Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA )
3 Jun 2013
Crizotinib and molecular testing in advanced non small cell lung cancer
Dr Fred Hirsch - University of Colorado, Denver, USA
Crizotinib and molecular testing in advanced non small cell lung cancer ( Dr Fred Hirsch - University of Colorado, Denver, USA )
3 Jun 2013
Nintedanib in combination with standard second line therapy in lung cancer
Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany
Nintedanib in combination with standard second line therapy in lung cancer ( Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany )
3 Jun 2013
Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for...
Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
3 Jun 2013
New targets for squamos cell carcinoma
Dr Martin Reck – Hospital Grosshansdorf, Wohrendamm, Germany
New targets for squamos cell carcinoma ( Dr Martin Reck – Hospital Grosshansdorf, Wohrendamm, Germany )
16 May 2013
Surgery in mesothelioma
Dr Paul Baas - Netherlands Cancer Institute, Amsterdam
Surgery in mesothelioma ( Dr Paul Baas - Netherlands Cancer Institute, Amsterdam )
16 May 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation